66 results on '"Bolenz C"'
Search Results
2. Prospective standardization of organoid-based pharmacotyping in urothelial carcinoma
3. Membranous NECTIN-4 expression in metastasis versus matched primary tumor more accurately predicts enfortumab vedotin response
4. LBA75 RACE IT: A prospective, single arm, multicenter, phase II-trial to assess safety and efficacy of preoperative RAdiation therapy before radical CystEctomy combined with ImmunoTherapy in locally advanced urothelial carcinoma of the bladder (AB 65/18) – first results
5. RACE IT - A prospective, single arm, multicenter, phase II-trial to assess safety and efficacy of preoperative RAdiation therapy before radical CystEctomy combined with ImmunoTherapy in locally advanced urothelial carcinoma of the bladder (AB 65/18)
6. Optimizing ureterorenoscopic biopsy quality in the upper urinary tract by cryobiopsy
7. Divergent immunobiological correlates of FDA-/EMA-approved PD-L1 assays and scoring algorithms in muscle-invasive bladder cancer
8. The potential for designing urothelial carcinomas using pluripotent stem cell-based systems
9. 758P Assessment of prognostic and predictive value of FGFR alterations (FGFRa) in a real-world cohort of patients (pts) with high-risk pT1 non-muscle-invasive bladder cancer (NMIBC)
10. Prognostic role of FGFR alterations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second line setting
11. Evaluation of different diagnostic methods for identification of FGFR alteration in advanced urothelial carcinomas: Proficiency results based on multiple RNA extraction kits and mutation detection methods
12. Prognostic role of FGFR Mutations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second-line setting
13. Efficacy of anti-PD(L)1 treatment in patients with metastatic urothelial cancer based on mRNA- and protein- based PD-L1 determination: Results from the multicentric, retrospective FOsMIC trial
14. Immunological microenvironment of FGFR3 altered muscle-invasive bladder cancer
15. Tumor immune microenvironment drives prognostic relevance correlating with bladder cancer subtypes
16. Development of a rodent model for preclinical evaluation of multiple contrast agents and real-time multispectral imaging in bladder cancer
17. Performance of FDA/EMA approved PD-L1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab
18. Androgen receptor mRNA expression in urothelial carcinoma of the bladder: A retrospective analysis of two independent cohorts
19. Prognostic Value of Molecular Breast Cancer Subtypes based on Her2, ESR1, PGR and Ki67 mRNA-Expression in Muscle Invasive Bladder Cancer
20. Cryobiopsy for upper urinary tract lesions: Preclinical evaluation of a novel device
21. Long non-coding RNAs as markers for prognosis and drug target gene expression in muscle-invasive bladder cancer
22. Multiparametric cystoscopy for the detection of bladder cancer using wide field multispectral imaging during TUR-B
23. Prognostic impact of tumor infiltrating lymphocytes and immune cell related gene expression after radical cystectomy in muscle-invasive bladder cancer
24. Is online patient information on bladder cancer websites in line with the EAU guidelines?
25. Long non-coding RNAs are differentially expressed between bladder cancer subtypes
26. Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of metastatic renal cell carcinoma (SWITCH-II)
27. Role of the crosstalk between tumor cells, vascular endothelium and the coagulation cascade for the invasion of urothelial bladder carcinoma
28. 516 Hospital but not surgical volume predicts 30- and 90-day complications in radical cystectomy (RC) – results from the prospective multicenter radical cystectomy series (PROMETRICS 2011) study group
29. 31 Generating panoramic images of the urinary bladder for the digital documentation of cystoscopy findings using Endorama®: Development and first clinical experience
30. 1152 Neoadjuvant chemotherapy before radical cystectomy in patients with urothelial carcinoma of the bladder: Current practice among clinicians
31. 17 Frequency and prognostic value of PTEN loss in patients with upper tract urothelial carcinoma
32. Prediction of outcome in patients with urothelial carcinoma of the bladder following radical cystectomy using artificial neural networks
33. 576 Prediction of cancer-specific survival after radical nephroureterectomy for upper tract urothelial carcinoma: Development of an optimized post-operative nomogram using decision curve analysis
34. 286 Clinical and pathological nodal staging score for urothelial carcinoma of the bladder are valid decision tools for risk assessment and clinical decision-making: An external validation
35. 1052 Differentiation of microvessels and lymphatic vessels in non seminomatous testicular germ cell tumors using lymph specific markers: Morphologic characteristics and clinical implications
36. External validation of disease-free survival at 2 or 3 years as a surrogate and new primary endpoint for patients undergoing radical cystectomy for urothelial carcinoma of the bladder
37. 775 Female gender is associated with worse cancer-specific survival after radical cystectomy for urothelial bladder carcinoma: Multicenter analysis of 2,483 patients
38. 872 External validation of disease-free survival at 2 or 3 years as a surrogate and new primary endpoint for patients undergoing radical cystectomy for muscle invasive urothelial carcinoma of the bladder
39. POD-01.01 Invasion of Urothelial Carcinoma Cells: Standardized Evaluation in a Novel Electrophysiological Assay
40. 489 NOVEL IN VITRO ASSAY FOR STANDARDIZED TRANSLATIONAL RESEARCH ON INVASIVE GROWTH OF UROTHELIAL CARCINOMA
41. 540 PREDICTORS OF PROGRESSION IN NON-MUSCLE- INVASIVE UROTHELIAL BLADDER CANCER FOLLOWING TRANSURETHRAL RESECTION: VALUE OF LYMPH- SPECIFIC PARAMETERS
42. 244 MULTICENTRIC VALIDATION OF NOMOGRAMS TO PREDICT LOCALLY ADVANCED UROTHELIAL CANCER OF THE BLADDER AND SURVIVAL RATES FOLLOWING RADICAL CYSTECTOMY
43. 866 ASSOCIATION BETWEEN THE EXTENT OF PELVIC LYMPHADENECTOMY AND CANCER-SPECIFIC SURVIVAL IN PATIENTS WITH LYMPH NODE NEGATIVE UROTHELIAL CARCINOMA OF THE BLADDER UNDERGOING RADICAL CYSTECTOMY
44. 243 PREDICTION OF LOCALLY ADVANCED BLADDER CANCER BEFORE CYSTECTOMY AND OUTCOME ASSESSMENT OF PATIENTS WITH BLADDER CANCER AFTER CYSTECTOMY USING ARTIFICIAL NEURAL NETWORKS
45. 915 THE INFLUENCE OF BODY MASS INDEX ON THE COST OF RADICAL PROSTATECTOMY FOR PROSTATE CANCER
46. 36 OUTCOME PREDICTION IN PATIENTS WITH BLADDER CANCER AFTER CYSTECTOMY USING ARTIFICIAL NEURAL NETWORKS
47. 915 CLINICAL MANAGEMENT OF ELDERLY PATIENTS WITH UROTHELIAL CARCINOMA OF THE BLADDER AT AN ACADEMIC INSTITUTION: DOES IT MEET CURRENT STANDARD OF CARE?
48. 537 CONTEMPORARY OUTCOMES OF RADICAL CYSTECTOMY AND PELVIC LYMPHADENECTOMY FOR TRANSITIONAL CELL CARCINOMA OF THE BLADDER
49. 671 PREDICTIVE VALUE OF THE COMBINATION OF IMMUNOSTOCHEMICAL MARKERS IN PATIENTS WITH PT1 DISEASE AT RADICAL CYSTECTOMY
50. 118 REMOVAL OF AT LEAST 8 NODES IMPROVES BOTH STAGING AND OUTCOMES IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.